Canakinumab Response in an Undifferentiated Autoinflammatory Disease With a Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Phenotype: A Case Report

We present a 38-year-old African American woman with hereditary C1 esterase inhibitor deficiency, diabetes mellitus, and a hypercoagulable disorder who presented to rheumatology clinic with recurrent inflammatory episodes starting around nine years old. Flares lasted several days to weeks and included subjective fever, painful facial and truncal rash, myalgias, polyarthritis, gastrointestinal symptoms, headache, and weakness. Flares were accompanied by elevated inflammatory markers and neutrophil-predominant leukocytosis. Infectious, autoimmune, and metabolic mimics were excluded, and autoinflammatory gene panel testing was never performed due to high costs to the patient. Several disease-modifying drugs were tried without benefit, while intermittent glucocorticoids were moderately effective. A tumor necrosis factor receptor-associated periodic syndrome (TRAPS)-like phenotype was suspected, and canakinumab, an anti-interleukin-1β (IL-1β) monoclonal antibody, was initiated at 150 milligrams (mg) every four weeks and eventually escalated to 150 mg every two weeks with symptom resolution. Undifferentiated autoinflammatory disease with a TRAPS-like phenotype is the presumed diagnosis as the patient fulfilled several clinical features of TRAPS and responded to IL-1β blockade. The disease has remained quiescent with no adverse events from canakinumab. In a patient with a phenotype fulfilling clinical criteria for TRAPS but no accessible genetic testing, a sustained response to IL-1β blockade with reproducible flare on withdrawal was both therapeutic and supportive in diagnosis. This case illustrates how administrative barriers to testing contribute to diagnostic challenges in a rare disease, and it adds long-term outcome data for canakinumab in an unconfirmed TRAPS-like autoinflammatory disease.

Authors

Publication Details

Journal
Cureus
Published
2026-11-19
DOI
https://doi.org/10.7759/cureus.119937
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Canakinumab Response in an Undifferentiated Autoinflammatory Disease With a Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Phenotype: A Case Report

David Maxwell, Morgan Agner
Cureus
Inflammasome and immune disorders
article

Canakinumab Response in an Undifferentiated Autoinflammatory Disease With a Tumor Necrosis Factor Receptor-Associated Periodic Syndrome Phenotype: A Case Report

David Maxwell, Morgan Agner
article en

Abstract

We present a 38-year-old African American woman with hereditary C1 esterase inhibitor deficiency, diabetes mellitus, and a hypercoagulable disorder who presented to rheumatology clinic with recurrent inflammatory episodes starting around nine years old. Flares lasted several days to weeks and included subjective fever, painful facial and truncal rash, myalgias, polyarthritis, gastrointestinal symptoms, headache, and weakness. Flares were accompanied by elevated inflammatory markers and neutrophil-predominant leukocytosis. Infectious, autoimmune, and metabolic mimics were excluded, and autoinflammatory gene panel testing was never performed due to high costs to the patient. Several disease-modifying drugs were tried without benefit, while intermittent glucocorticoids were moderately effective. A tumor necrosis factor receptor-associated periodic syndrome (TRAPS)-like phenotype was suspected, and canakinumab, an anti-interleukin-1β (IL-1β) monoclonal antibody, was initiated at 150 milligrams (mg) every four weeks and eventually escalated to 150 mg every two weeks with symptom resolution. Undifferentiated autoinflammatory disease with a TRAPS-like phenotype is the presumed diagnosis as the patient fulfilled several clinical features of TRAPS and responded to IL-1β blockade. The disease has remained quiescent with no adverse events from canakinumab. In a patient with a phenotype fulfilling clinical criteria for TRAPS but no accessible genetic testing, a sustained response to IL-1β blockade with reproducible flare on withdrawal was both therapeutic and supportive in diagnosis. This case illustrates how administrative barriers to testing contribute to diagnostic challenges in a rare disease, and it adds long-term outcome data for canakinumab in an unconfirmed TRAPS-like autoinflammatory disease.

Cureus
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon